Paget's disease of bone.
Paget's disease affects approximately 3% of the population over age forty. It may be genetically transmitted (autosomal-dominant), but recent evidence suggests a viral etiology. Effective agents for control of the disorder have been developed over the past decade, but all have significant drawbacks. Calcitonin tends to lose its effectiveness in significant numbers of patients over a few months, mithramycin has significant toxicity, and diphosphonates tend to cause osteomalacia.
D000328:Adult; D001842:Bone and Bones / Q000098:blood supply / Q000473:pathology; D002116:Calcitonin / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D003094:Collagen; D003609:Dactinomycin / Q000627:therapeutic use; D012968:Etidronic Acid / Q000627:therapeutic use; D005459:Fluorides / Q000627:therapeutic use; D005934:Glucagon / Q000627:therapeutic use; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D010001:Osteitis Deformans / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000627:therapeutic use; D010710:Phosphates / Q000627:therapeutic use; D008926:Plicamycin / Q000627:therapeutic use; D012039:Regional Blood Flow
D010281:Parathyroid Hormone; D010710:Phosphates; D003609:Dactinomycin; D002116:Calcitonin; D003094:Collagen; D005934:Glucagon; D012968:Etidronic Acid; D008926:Plicamycin; D005459:Fluorides; D006909:Hydroxyproline; D002118:Calcium